Abiopharma

🔍 Singh Jesse G (Director)

Company: CARLISLE COMPANIES INC (CSL)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Acquired 16 shares of Restriced Stock Units (Derivative)
  Date: 2026-09-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,070.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2
• Acquired 13 shares of Deferred Stock Units (Derivative)
  Date: 2026-09-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 13.00 | transaction_form_type: 4 | Footnotes: F3, F4, F3, F3

Footnotes:

• F1: Represents additional restricted stock units acquired as a result of the quarterly dividend declared and paid by the issuer. Each restricted stock unit represents a right to receive one share of the issuer's common stock.
• F2: The restricted stock units were fully vested on the date of grant and the vested shares will be delivered to the reporting person upon the reporting person's termination of service as a director of the issuer.
• F3: Each deferred stock unit is the economic equivalent of one share of the issuer's common stock. The deferred stock units become payable in cash upon the reporting person's termination of service as a director of the issuer, such payment to be made in a lump sum or in quarterly installments over ten years based upon the closing price of the issuer's common stock on the payment date.
• F4: Represents additional deferred stock units acquired as a result of the quarterly dividend declared and paid by the issuer.